Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 115, Issue 1, 2009, Pages 131-136

  Gennari, Alessandra ^a   De Tursi, Michele ^b   Carella, Consiglia ^b   Ricevuto, Enrico ^c   Orlandini, Cinzia ^d   Frassoldati, Antonio ^e   Conte, Pierfranco ^e   Bruzzi, Paolo ^a   Iacobelli, Stefano ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Epirubicin; Low dose trastuzumab; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; TRASTUZUMAB;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; FEBRILE NEUTROPENIA; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEUKOPENIA; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; TIME FACTORS; TREATMENT OUTCOME;

EID: 67349113494     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0048-8     Document Type: Article

References (21)

1. CL Vogel MA Cobleigh D Tripathy 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719 726
2. CA Hudis 2007 Trastuzumab-mechanism of action and use in clinical practice N Engl J Med 357 39 51
3. DJ Slamon B Leyland-Jones S Shak 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792
4. MA Cobleigh CL Vogel D Tripathy 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639 2648
5. B Leyland-Jones K Gelmon JP Ayoub 2003 Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel J Clin Oncol 21 3965 3971
6. P Carter L Presta CM Gorman 1992 Humanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 4285 4289
7. P Therasse SG Arbuck EA Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 2016
8. R Simon 1989 Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 10
9. R Fossati C Confalonieri V Torri 1998 Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women J Clin Oncol 6 3439 3460
10. RL Jones C Swanton MS Ewer 2006 Anthracycline cardiotoxicity Expert Opin Drug Saf 5 791 809
11. MS Ewer 2007 The anthracycline-trastuzumab interaction: up-regulated binding may provide vital mechanistic insight Eur J Cancer 43 2024 2025
12. L Gianni E Salvatorelli G Minotti 2007 Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes Cardiovasc Toxicol 7 67 71
13. KR Chien 2006 Herceptin and the heart-a molecular modifier N Engl J Med 354 789 799
14. Y Yoshiyama T Sugiyama M Kanke 2003 Cardiotoxicity of trastuzumab (herceptin) in chick embryos Biol Pharm Bull 26 893 895
15. M Untch S Tjulandin W Jonat 2007 Cardiac safety of trastuzumab in combination with epirubicin cyclophosphamide as first-line therapy in patients with HER2 positive metastatic breast cancer Eur J Cancer 5 216
16. S Chia M Clemons L Martin 2006 Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II study J Clin Oncol 24 2773 2778
17. HA Burris HI Hurwitz EC Dees 2005 Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas J Clin Oncol 23 5305 5313
18. B Moy PE Goss 2007 Lapatinib-associated toxicity and practical management recommendations Oncologist 12 756 765
19. HJ Burstein A Keshaviah AD Baron 2007 Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study Cancer 110 965 972
20. FJ Esteva V Valero D Booser 2002 Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer J Clin Oncol 20 1800 1808
21. M Marty F Cognetti D Maraninchi 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 4265 4274